Année
2022
Auteurs
PUYOU DE POUVOURVILLE Gérard, CHOQUET Sylvain, DESLANDES Marine, MACHER Nahid, MARCHAL Clarisse, BELHASSEN Manon, JACOUD Flore, LEVY Vincent
Abstract
Ibrutinib is a Bruton’s Tyrosine Kinase Inhibitor indicated in the treatment of several B-cell malignancies: Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) and Waldenström Macroglobulinemia (WM). The number and the characteristics of patients treated by Ibrutinib in France in real life settings are unknown and need to be determined, as well as treatment pattern in real-life settings.
CHOQUET, S., DESLANDES, M., MACHER, N., PUYOU DE POUVOURVILLE, G., MARCHAL, C., BELHASSEN, M. … LEVY, V. (2022). Use of Ibrutinib in Real Life Settings in France: Results from a Retrospective Observational Study Using the Snds Database (OSIRIS). Dans: American Society of Hematology Conference.